Cronos Group Inc. is a cannabinoid company involved in the cultivation, production, and marketing of cannabis products globally. Its strengths include a strong gross margin of 53.7% and a solid current ratio of 16.18, indicating excellent liquidity. However, concerns arise from a low return on equity (3.0%) and a recent stock decline of 3.93%, which may reflect market apprehension despite high margins. The disparity between high profitability metrics and the current stock price suggests potential undervaluation, warranting further investigation into market sentiment and growth prospects.
Loading financial metrics...
No significant red flags identified
This company appears financially healthy on available metrics
Exceptional revenue growth of 37.6% YoY demonstrates strong market demand and competitive positioning.
Gross margin expanded by 9.1 percentage points, indicating improved pricing power or cost efficiency.
Operating margin expanded by 40.2pp, demonstrating strong operational leverage.
Both gross margin (+9.1pp) and operating margin (+40.2pp) are expanding simultaneously, indicating the company is scaling profitably.
Operating cash flow surged 199.9% YoY, indicating strong cash generation capability.
Valuation, risk assessment, competitive positioning, and key insights — all in one report.
Other Drug Manufacturers - Specialty & Generic companies of a similar size
Based on 2026-Q2 (June 30, 2026)